Another facet to the anticancer response to lamellarin D: Induction of cellular senescence through inhibition of topoisomerase i and intracellular ros production

Marine Drugs

Volumn 12, Issue 2, 2014, Pages 779-798

  Ballot, Caroline ^a,b   Martoriati, Alain ^a   Jendoubi, Manel ^a   Buche, Sébastien ^a   Formstecher, Pierre ^a   Mortier, Laurent ^a   Kluza, Jérome ^a   Marchetti, Philippe ^a,b  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cellular senescence; DNA damage; Mitochondria; Oxidative stress response

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; DNA TOPOISOMERASE; GLUTATHIONE; LAMELLARIN D; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CELL AGING; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CHROMOSOME LOSS; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; NONHUMAN; OSTEOSARCOMA CELL; TELOMERE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; CELL LINE, TUMOR; COUMARINS; DNA TOPOISOMERASES, TYPE I; DNA, MITOCHONDRIAL; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; ISOQUINOLINES; MICE, SCID; MITOCHONDRIA; NEOPLASMS; REACTIVE OXYGEN SPECIES; TELOMERE; TOPOISOMERASE INHIBITORS;

EID: 84896706140     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md12020779     Document Type: Article

References (37)

1. Simmons, T.L.; Andrianasolo, E.; McPhail, K.; Flatt, P.; Gerwick, W.H. Marine natural products as anticancer drugs. Mol. Cancer Ther. 2005, 4, 333-342.
2. Xiong, Z.-Q.; Wang, J.-F.; Hao, Y.-Y.; Wang, Y. Recent advances in the discovery and development of marine microbial natural products. Mar. Drugs 2013, 11, 700-717.
3. Cioffi, A.; Italiano, A. Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma. Expert Opin. Drug Metab. Toxicol. 2012, 8, 113-122.
4. Kasper, B.; Schmitt, T.; Wuchter, P.; Dimitrakopoulou-Strauss, A.; Ho, A.D.; Egerer, G. The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin. Mar. Drugs 2009, 7, 331-340.
5. Suarez, Y.; González, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Muñoz, A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol. Cancer Ther. 2003, 2, 863-872.
6. Kluza, J.; Marchetti, P.; Bailly, C. Lamellarin Alkaloids: Structure, Isolation, Synthesis and Biology; Fattorusso, E., Taglialatela-Scafati, O., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2008; pp. 171-187.
7. Bailly, C. Lamellarins, from A to Z: A family of anticancer marine pyrrole alkaloids. Curr. Med. Chem. Anticancer Agents 2004, 4, 363-378.
8. Kluza, J.; Gallego, M.-A.; Loyens, A.; Beauvillain, J.-C.; Sousa-Faro, J.-M.; Cuevas, C.; Marchetti, P.; Bailly, C. Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. Cancer Res. 2006, 66, 3177-3187.
9. Facompré, M.; Tardy, C.; Bal-Mahieu, C.; Colson, P.; Perez, C.; Manzanares, I.; Cuevas, C.; Bailly, C. Lamellarin D: A novel potent inhibitor of topoisomerase I. Cancer Res. 2003, 63, 7392-7399.
10. Baunbæk, D.; Trinkler, N.; Ferandin, Y.; Lozach, O.; Ploypradith, P.; Rucirawat, S.; Ishibashi, F.; Iwao, M.; Meijer, L. Anticancer alkaloid lamellarins inhibit protein kinases. Mar. Drugs 2008, 6, 514-527.
11. Ballot, C.; Kluza, J.; Lancel, S.; Martoriati, A.; Hassoun, S.M.; Mortier, L.; Vienne, J.-C.; Briand, G.; Formstecher, P.; Bailly, C.; et al. Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D. Apoptosis 2010, 15, 769-781.
12. Ballot, C.; Kluza, J.; Martoriati, A.; Nyman, U.; Formstecher, P.; Joseph, B.; Bailly, C.; Marchetti, P. Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D. Mol. Cancer Ther. 2009, 8, 3307-3317.
13. Ballot, C.; Jendoubi, M.; Kluza, J.; Jonneaux, A.; Laine, W.; Formstecher, P.; Bailly, C.; Marchetti, P. Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II. Apoptosis 2012, 17, 364-376.
14. Wang, Y.; Blandino, G.; Oren, M.; Givol, D. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene 1998, 17, 1923-1930.
15. Dimri, G.P. What has senescence got to do with cancer? Cancer Cell. 2005, 7, 505-512.
16. Dimri, G.P.; Lee, X.; Basile, G.; Acosta, M.; Scott, G.; Roskelley, C.; Medrano, E.E.; Linskens, M.; Rubelj, I.; Pereira-Smith, O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995, 92, 9363-9367.
17. Kluza, J.; Corazao-Rozas, P.; Touil, Y.; Jendoubi, M.; Maire, C.; Guerreschi, P.; Jonneaux, A.; Ballot, C.; Balayssac, S.; Valable, S.; et al. Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res. 2012, 72, 5035-5047.
18. Han, Z. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 2002, 277, 17154-17160.
19. Ewald, J.A.; Desotelle, J.A.; Wilding, G.; Jarrard, D.F. Therapy-induced senescence in cancer. J. Natl. Cancer Inst. 2010, 102, 1536-1546.
20. Orrenius, S.; Gogvadze, V.; Zhivotovsky, B. Mitochondrial oxidative stress: Implications for cell death. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 143-183.
21. Blackman, R.K.; Cheung-Ong, K.; Gebbia, M.; Proia, D.A.; He, S.; Kepros, J.; Jonneaux, A.; Marchetti, P.; Kluza, J.; Rao, P.E.; et al. Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS One 2012, 7, e29798.
22. Chang, B.D.; Broude, E.V.; Dokmanovic, M.; Zhu, H.; Ruth, A.; Xuan, Y.; Kandel, E.S.; Lausch, E.; Christov, K.; Roninson, I.B. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999, 59, 3761-3767.
23. Roninson, I.B. Tumor cell senescence in cancer treatment. Cancer Res. 2003, 63, 2705-2715.
24. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J.P.; Sedivy, J.M.; Kinzler, K.W.; Vogelstein, B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282, 1497-1501.
25. Gewirtz, D.A.; Holt, S.E.; Elmore, L.W. Accelerated senescence: An emerging role in tumor cell response to chemotherapy and radiation. Biochem. Pharmacol. 2008, 76, 947-957.
26. Pelicano, H.; Carney, D.A.; Huang, P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat. 2004, 7, 97-110.
27. Achuthan, S.; Santhoshkumar, T.R.; Prabhakar, J.; Nair, S.A.; Pillai, M.R. Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J. Biol. Chem. 2011, 286, 37813-37829.
28. Probin, V.; Wang, Y.; Zhou, D. Busulfan-induced senescence is dependent on ROS production upstream of the MAPK pathway. Free Radic. Biol. Med. 2007, 42, 1858-1865.
29. Lambeth, J.D.; Krause, K.H.; Clark, R.A. NOX enzymes as novel targets for drug development. Semin. Immunopathol. 2008, 30, 339-363.
30. Weyemi, U.; Lagente-Chevallier, O.; Boufraqech, M.; Prenois, F.; Courtin, F.; Caillou, B.; Talbot, M.; Dardalhon, M.; Al Ghuzlan, A.; Bidart, J.-M.; et al. ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene 2011, 31, 1117-1129.
31. Luo, H.; Wang, L.; Schulte, B.A.; Yang, A.; Tang, S.; Wang, G.Y. Resveratrol enhances ionizing radiation-induced premature senescence in lung cancer cells. Int. J. Oncol. 2013, 43, 1999-2006.
32. Kang, M.A.; So, E.-Y.; Simons, A.L.; Spitz, D.R.; Ouchi, T. DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway. Cell Death Dis. 2012, 3, e249.
33. Madelaine, I.; Prost, S.; Naudin, A.; Riou, G.; Lavelle, F.; Riou, J.F. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem. Pharmacol. 1993, 45, 339-348.
34. Debacq-Chainiaux, F.; Erusalimsky, J.D.; Campisi, J.; Toussaint, O. Protocols to detect senescence-associated β-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo. Nat. Protoc. 2009, 4, 1798-1806.
35. Huang, X.; Darzynkiewicz, Z. Cytometric assessment of histone H2AX phosphorylation: A reporter of DNA damage. Methods Mol. Biol. 2006, 314, 73-80.
36. Castera, L.; Hatzfeld-Charbonnier, A.S.; Ballot, C.; Charbonnel, F.; Dhuiege, E.; Velu, T.; Formstecher, P.; Mortier, L.; Marchetti, P. Apoptosis-related mitochondrial dysfunction defines human monocyte-derived dendritic cells with impaired immuno-stimulatory capacities. J. Cell. Mol. Med. 2009, 13, 1321-1335.
37. Elmore, L.W.; Rehder, C.W.; Di, X.; McChesney, P.A.; Jackson-Cook, C.K.; Gewirtz, D.A.; Holt, S.E. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem. 2002, 277, 35509-35515.